Acuta Capital Partners’s Tourmaline Bio TRML Stock Holding History

Acuta Capital Partners’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-268,451	Closed	-$12.8M	–	35
2025 Q3	$12.8M	Sell	268,451 -15,231	-5%	-$422K	13.27%	3
2025 Q2	$4.54M	Sell	283,682 -143,200	-34%	-$2.32M	6.33%	5
2025 Q1	$6.49M	Buy	426,882 +75,040	+21%	+$1.2M	7.53%	3
2024 Q4	$7.14M	Buy	351,842 +19,747	+6%	+$497K	7.18%	3
2024 Q3	$8.54M	Buy	332,095 +62,481	+23%	+$1.04M	6.92%	3
2024 Q2	$3.47M	Buy	269,614 +8,506	+3%	+$137K	2.92%	12
2024 Q1	$5.98M	Buy	261,108 +29,226	+13%	+$1.03M	3.88%	9
2023 Q4	$6.07M	Buy	+231,882	New	+$4.64M	3.42%	12

Acuta Capital Partners's TRML Position: Q4 2025 in Review

Acuta Capital Partners sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 268,451 shares — an estimated $12.8M sold.

Acuta Capital Partners first reported a position in TRML in Q4 2023 and held it in 8 quarters. The position peaked at $12.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Acuta Capital Partners reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Acuta Capital Partners sold 268,451 Tourmaline Bio shares in Q4 2025, an estimated $12.8M.
Acuta Capital Partners first reported a position in Tourmaline Bio in Q4 2023 and held it in 8 quarters.
Acuta Capital Partners's Tourmaline Bio position peaked at $12.8M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.